Curis, Inc. 4 Maguire Road Lexington,
MA 02421 United States - Map Phone: 617-503-6500 Fax: 617-503-6501 Website: http://www.curis.com
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts. Key Statistics
| |
| Curis, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 5. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Daniel R. Passeri MSc., J.D.,
52 Chief Exec. Officer and Director | 611.00K | 248.00K | Mr. Michael P. Gray ,
42 Chief Financial Officer, Principal Accounting Officer and Sec. | 451.00K | 225.00K | Mr. Mark W. Noel ,
54 VP of Technology Management and Intellectual Property | 276.00K | 399.00K | Dr. Maurizio Voi M.D.,
55 Chief Devel. Officer, Chief Medical Officer and Exec. VP | 585.00K | 0.00 | Dr. Ali Fattaey Ph.D.,
48 Pres and Chief Operating Officer | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|